(MCRC Clinical) Gut-Immune-Leukaemia Crosstalk in Aged AML: Mechanisms of Response to p38 MAPK-Targeted Combination Therapy
The University of Manchester
Division of Cancer Sciences
Acute myeloid leukaemia (AML) predominantly affects older patients, who tolerate intensive curative therapy poorly and are typically treated with non-curative regimens involving azacitidine (AZA), alone or with the BCL-2 inhibitor venetoclax (VEN). Read more
Supervisors: Dr SV Valletta, Dr A Virós, Dr JL Loke, Dr EG Giampazolias
23 November 2026
PhD Research Project
Competition Funded PhD Project (Students Worldwide)